NCT01642095

Brief Summary

This laboratory study is looking into biomarkers in samples from younger patients with kidney cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 15, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 17, 2012

Completed
1 month until next milestone

Study Start

First participant enrolled

August 22, 2012

Completed
10 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2012

Completed
Last Updated

August 7, 2018

Status Verified

October 1, 2017

Enrollment Period

10 days

First QC Date

July 15, 2012

Last Update Submit

August 3, 2018

Conditions

Childhood Kidney NeoplasmClear Cell Renal Cell CarcinomaCongenital Mesoblastic NephromaRhabdoid Tumor of the Kidney

Outcome Measures

Primary Outcomes (1)

  • FAK expression in pediatric renal tumors

    Baseline

Study Arms (1)

Basic science (FAK expression)

Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.

Other: Laboratory Biomarker Analysis

Interventions

Laboratory Biomarker AnalysisOTHER

Correlative studies

Basic science (FAK expression)

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample

You may qualify if:

  • Formalin-fixed, paraffin-embedded tissue samples from patients diagnosed with the following renal tumors:
  • Anaplastic Wilms tumor
  • Malignant rhabdoid tumor of the kidney
  • Clear cell sarcoma of the kidney
  • Mesoblastic nephroma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Childrens Oncology Group

Philadelphia, Pennsylvania, 19104, United States

Location

MeSH Terms

Conditions

Carcinoma, Renal CellNephroma, Mesoblastic

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital DiseasesNeoplasms, Complex and Mixed

Study Officials

  • Elizabeth Beierle

    Children's Oncology Group

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 15, 2012

First Posted

July 17, 2012

Study Start

August 22, 2012

Primary Completion

September 1, 2012

Last Updated

August 7, 2018

Record last verified: 2017-10

Locations

US(1)